Capricor Therapeutics CAPR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$105.04M-160% | -$40.47M-81.6% | -$22.29M+23.2% | -$29.02M-44.9% | ||
| $1.89M+32.5% | $1.43M+33.3% | $1.07M+100% | $533.13K+117% | ||
| $16.97M+73.8% | $9.77M+32.1% | $7.39M+65.8% | $4.46M+50.3% | ||
| -$69.81M-74.5% | -$40M-56.3% | -$25.6M— | —— | ||
| $2.9M+149% | $1.17M-11.0% | $1.31M-34.4% | $2M+67.2% | ||
| $97.48M+184% | -$116.18M— | —— | —— | ||
| $248.89M+62.9% | $152.77M+497% | $25.58M+425% | $4.87M-75.9% | ||
| —— | —— | —— | -$26.47M— | ||
| -$72.72M-76.7% | -$41.16M-53.0% | -$26.91M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Capricor Therapeutics's cash flow data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.